Here are the DEF 14A proxy statements from Hims & Hers Health, Inc. (HIMS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow HIMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIMS filings page.
Hims & Hers Health, Inc. is asking stockholders to vote at its June 11, 2026 virtual annual meeting on three items: electing nine directors, ratifying KPMG LLP as auditor for 2026, and approving executive pay on an advisory basis. The Board unanimously recommends voting “FOR” all proposals.
The proxy highlights strong 2025 performance, with revenue of $2.35 billion, up 59% year over year, and more than 2.5 million subscribers, up 13%. Net income was $128.4 million, compared with $126.0 million in 2024, while Adjusted EBITDA reached $318.0 million. Operating cash flow was $300.0 million and Free Cash Flow was $57.4 million.
The company is a NYSE “controlled company” because CEO Andrew Dudum, through Class A and high-vote Class V shares, holds over 50% of voting power and approximately 87.7% of total voting power. Despite this status, a majority of directors are independent, and all audit and compensation committee members are independent. The proxy also describes board committee structures, risk oversight, diversity metrics, and a pay program that is heavily equity-based and performance-linked, with executives earning about 94% of target 2025 bonuses based on revenue and Adjusted EBITDA results.